Lacerta Bio is pleased to present two novel antibiotics with excellent properties on behalf of our client.
The first is a peptide antibiotic which inhibits cell wall synthesis, making it suitable for the intravenous treatment of troublesome Gram Positive bacteria, such as MRSA, VRE, and many other resistant pathogens.
The second is a liposlycodepsipeptide suitable for the intravenous treatment of infections caused by drug-resistant Gram Positive bacteria, including MRSA and VRE.
Importantly, its high water solubility makes it suitable for the development of ophthalmic formulations.
Both compounds have novel mechanisms of action, and exhibit superior efficacy in Preclinical models in comparison to established, and increasingly ineffective, antibiotics.
Both also have activity against select Gram Negative and Anaerobic pathogens, so both can be thought of as broad-spectrum, potentially first-line agents in the hospital setting.
For more information, contact us via the form below: